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Summary
Cancer of an unknown primary site is most commonly an aggressive metastatic tumor with a median patient survival 
of 6 to 9 months. Histologically, it is predominantly adenocarcinoma, and if the primary site is subsequently diagnosed, it 
is usually the pancreas or lung. Biopsy should be performed whenever possible to classify a tumor of unknown primary 
origin into one of the following entities: adenocarcinoma, poorly differentiated carcinoma with characteristics similar to 
adenocarcinoma, squamous cell carcinoma, neuroendocrine carcinoma, poorly differentiated neoplasm. After determining 
the primary tumor type, the subtype is determined by immunohistochemical staining. In oligometastatic disease, there is a 
possibility of surgical treatment. Radiotherapy is used as a part of combined modality treatment. Most patients with cancer 
of unknown primary have an unfavorable prognosis despite multiple chemotherapy agents, and no protocol can be recom-
mended as standard therapy.
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INTRODUCTION
Cancer of unknown primary (CUP) is a clini-
cal-pathological syndrome characterized by histo-
logically proven metastatic cancer without a clini-
cally found primary site of origin (1). Most of these 
cancers have a primary occult site but with a met-
astatic ability (1). These tumors are considered 
 aggressive, disseminate early, and with an un-
predictable pattern, leaving these patients’ life ex-
pectancy short, with a median survival of 6 to 9 
months (2,3).
In 2017, 604 newly diagnosed patients with 
cancer of unknown primary in Croatia accounted 
for 2.4% of all newly diagnosed cancer patients. 
54.0% of these patients presented with distant me-
tastases, and 27.1% of them with unknown disease 
stages (4). Histologically, most of the cancers of 
unknown primary are adenocarcinomas (50–70%), 
fewer are undifferentiated carcinoma (20–30%), 
squamous cell carcinoma (5–8%), and undifferen-
tiated tumors (2–3%) (5). When and if the primary 
site is diagnosed, most common are pancreas (20–
26%), lung (17-23%), liver (3-11%), colon (4–10%), 
gastric (3–8%), kidney (4–6%), ovary (3–4%), pros-
tate (3–4%) and breast cancer (2%) (6).
Clinical presentation and prognosis
Over 50% of patients with cancer of unknown 
primary have more than one site of metastatic in-
volvement, mostly liver, lymph nodes, bones, 
lungs. This type of cancer can metastasize to any 
site, making the pattern of metastasis inadequate 
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to determine tumor origin (7). The clinical presen-
tation depends on metastases’ location and can be 
followed by non-specific symptoms such as fa-
tigue and weight loss. Most patients present with 
pain (60%), enlarged liver or abdominal symp-
toms (40%), palpable lymph nodes (20%), bone 
pain or fracture (15%), lung symptoms (15%), or 
CNS abnormalities (5%) (8).
In general, CUP prognostic factors that are 
considered negative are male gender; more than 
three metastatic sites; performance status two or 
more; metastases outside of lymph nodes; elevat-
ed LDH, lymphopenia, low serum albumins, and 
unfavorable CUP subset (9,10).
Clinical investigation
Firstly, a thorough medical history, includ-
ing family history, should be taken alongside a 
physical exam with an accent on breast, lymph 
node, skin, genitalia, rectum, and pelvis examina-
tion (11).
Complete laboratory workup should be per-
formed, including full blood count, liver and kid-
ney function tests, bone profiling, serum LDH, 
and urine test. The routine tumor markers CEA, 
CA 125, CA 19-9, and CA 15-3 are not advised as 
these markers are not specific enough. However, 
they can be useful in specific situations such as 
PSA tests in male patients with bone metastases, 
βhCG and αFP in midline nodal disease, or CA125 
in female patients with peritoneal malignancy and 
ascites (11).
Chest, abdomen, and pelvis CT is recom-
mended for all patients with CUP. Endoscopy is 
advised based on clinical symptoms (11).
Positron emission tomography can be per-
formed in selected cases (squamous carcinoma in 
cervical/inguinal nodes and those with a single 
site involved). If ordered, it should be performed 
before EUS or biopsy/FNA/tonsillectomy to iden-
tify potential primary sites before any interven-
tion occurs. Mammography should be done in fe-
male patients, even a breast MRI if breast cancer is 
highly suspected. Other evaluation should be 
based on findings from the initial diagnostic eval-
uation, such as colonoscopy in patients with fea-
tures associated with colon cancer (peritoneal/ 
liver metastases, biopsy CK20+, CK7-, CDX2+), 
bronchoscopy (patients with mediastinal/hilar 
 adenopathy, biopsy CK7+), testicular ultrasound 
(young patients with mediastinal and/or retroper-
itoneal masses) and others (1).
A biopsy should be performed whenever it is 
possible. The light microscope classification of 
CUP includes adenocarcinoma (60%), poorly dif-
ferentiated carcinoma with features similar to ad-
enocarcinoma (30%), squamous cell cancer (5%), 
neuroendocrine carcinoma (3%), and poorly dif-
ferentiated neoplasm (2%). Additionally, immu-
nohistochemistry (IHC) can be useful in obtaining 
an accurate diagnosis. Given the numerous IHC 
staining markers, a stepwise approach is advised. 
Firstly by determining the main type of cancer 
(carcinoma, lymphoma, melanoma, sarcoma), 
then identify the subtype using specific IHC stain-
ing based on the light microscope finding and 
clinical features. Gathering multiple stains usually 
consumes the sample and rarely improves the di-
agnosis. Table 1 shows IHC stain patterns of single 
cancer or tissue of origin (1,12).
Several molecular assays are available in the 
USA based on the gene expression profile that pro-
vides a molecular classification of numerous cancer 
types with high accuracy rates (87%-90%) (1).
Treatment
CUP subgroups have been identified based 
on the patient’s gender, metastatic sites, histologic 
classification, and IHC staining and molecular 
cancer classifier assays. For patients with a favor-
able prognosis, subgroup-specific treatment op-
tions based upon presumptive diagnoses exist. 
However, over 80% of patients fall into the unfa-
vorable subgroup, where no efficient therapy has 
yet been identified. Some of the favorable subsets 
that will be described below include extragonadal 
germ cell cancer syndrome, axillary carcinoma in 
women, squamous cell carcinoma in upper cervi-
Table 1.
IHC stain patterns of single cancer or tissue of origin.
Lung cancer  
and large cell
CK7+, CK20-, TTF-1+, NapsinA+
Breast cancer CK7+, CK20-, GCDFP-15+, 
mammoglobin+, ER+, PR+, GATA3+, 
Her-2/neu+
Prostate cancer CK7-, CK20-, PSA+,
Germ cell PLAP+, OCT4+, SALL4+
Melanoma MelanA+, HMB45+, S100+
Colorectal cancer CK7-, CK20-, CDX2+
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cal/neck nodes and pelvic lymph nodes, men with 
osteoblastic metastases, and elevated PSA, neuro-
endocrine and peritoneal carcinoma (1,9).
Extragonadal germ cell cancer syndrome is a 
rare subset mostly found in young men involving 
the midline distribution (mediastinal and/or retro-
peritoneum) of poorly differentiated carcinoma. 
However, even if the histology is atypical, germ 
cell carcinoma therapy is indicated (1).
Axillary carcinoma in women, rarely men, 
usually indicates occult breast cancer, with nega-
tive radiographic findings. These patients should 
be treated like stage II or III breast carcinoma, see-
ing as their prognoses are similar (1).
Squamous cell carcinoma in upper cervical/
neck nodes is highly suggestive of occult head and 
neck carcinoma, and the treatment depends on the 
N stage of the disease. N1 disease neck dissection 
is the preferred treatment (with adjuvant treat-
ment depending on the postoperative pathology 
report), while ≥N2 can be treated surgically or us-
ing concurrent chemoradiotherapy (1). If defini-
tive surgery is planned, a biopsy of suspected ar-
eas plus tonsillectomy for the occult primary is 
advisable. In inguinal or pelvic lymph nodes, 
squamous cell carcinoma most likely arises for an 
occult uterine, anal, or vulva primary. Combined 
modality therapy is recommended (1).
Men with elevated PSA levels and osteoblas-
tic metastases should receive hormonal therapy 
for prostate cancer. Even men with osteoblastic 
metastases and normal PSA levels can receive hor-
monal therapy in selected clinical settings (1).
Treatment for neuroendocrine carcinoma de-
pends on the tumor grade. Well-differentiated tu-
mors are treated similar to carcinoid tumors. 
Poorly differentiated should be treated with cis-
platin- or carboplatin-based chemotherapy simi-
lar to small cell lung cancer (1).
Peritoneal carcinoma in women (rarely men) 
is usually adenocarcinoma and should be treated 
like ovarian cancer stage FIGO III. Patients with a 
single small cell can be treated locally with sur-
gery and/or radiotherapy. Adenocarcinoma with 
colon cancer profile should be treated the same as 
patients with metastatic colon adenocarcinoma 
since this improves their outcome (1).
Surgery can be performed in individual pa-
tients with CUP, particularly in the favorable sub-
set. The multidisciplinary team should discuss 
patients with a single brain, liver, lung, or skin 
metastasis to review surgery’s possibility because 
what appears to be a metastasis could easily be a 
primary tumor (11).
Radiation therapy can be a part of standard 
multimodal treatment for patients with isolated 
inguinal lymphadenopathy after surgery or pa-
tients with squamous cell metastases in neck 
lymph nodes. It can also be used for palliative 
purposes, such as spinal cord compression or su-
perior vena cava syndrome (11).
The unfavorable subset group includes meta-
static adenocarcinoma in the liver, squamous cell 
cancer of the abdominal/peritoneal cavity, malig-
nant ascites (nonpapillary), multiple brain, lung/
pleural, or bone metastases (1).
Most patients with CUP have an unfavorable 
prognosis, despite combined chemotherapeutic 
therapy. It has been shown that most patients re-
spond to therapy based on platinum, so doublets 
with platinum and new-generation compounds 
such as taxanes or gemcitabine may be a reason-
able choice (6,12). Triplets are considered more 
toxic and are not recommended (13,14). Empirical 
chemotherapy should be reserved for patients 
whose molecular profile is unable to predict tu-
mor origin (15).
CONCLUSION
Cancer of unknown primary remains a com-
plex diagnostic as well as a therapeutic challenge. 
Most patients still have a poor prognosis despite 
multimodal treatment. There are still no standard 
chemotherapy protocols that would make signi-
ficant progress in survival. Dual platinum che-
motherapy is the most common choice because 
the addition of a third agent has not shown sur-
vival benefit. It is essential to identify CUP pa-
tients subgroups that can benefit from a specific 
treatment procedure, avoiding unnecessary diag-
nostic procedures. Multimodal treatment with 
surgery, radiotherapy, and chemotherapy repre-
sents the best modality treatment for cancer of un-
known primary.
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Sažetak
LIJEČENJE TUMORA NEPOZNATOG PRIMARNOG SIJELA
I. Andrašek, M. Ravlić, M. Mikulandra, F. Cmrečak,  
S. Bilić Knežević i L. Beketić-Orešković
Rak nepoznatog primarnog sijela je najčešće agresivni metastatski tumor sa srednjim preživljenjem bolesnika od 6 do 
9 mjeseci. Histološki se uglavnom radi o adenokarcinomu, a ako se dijagnosticira primarno sijelo, to je najčešće gušterača ili 
pluća. Kad god je to moguće, potrebno je učiniti biospiju, kako bi se tumor nepoznatog primarnog sijela klasificirao na jedan 
od slijedećih entiteta: adenokarcinom, slabo diferencirani karcinom s karakteristikama sličnim adenokarcinomu, karcinom 
pločastih stanica, neuroendokrini karcinom ili slabo diferencirani tumor. Nakon određivanja glavnog tipa tumora, pomoću 
imunohistokemijskih metoda određuje se podtip. Kod oligometastatske bolesti postoji mogućnost kirurškog liječenja. 
Radio terapija se koristi kao dio multimodalnog liječenja. Većina bolesnika s tumorom nepoznatog primarnog sijela ima 
nepovoljnu prognozu, unatoč primjeni više kombinacija kemoterapijskih lijekova, a niti jedan protokol se ne može preporu-
čiti kao standardna terapija.
KLJUČNE RIJEČI: rak nepoznatog primarnog sijela, prognoza, liječenje
